Answers are grounded in this paper and cite their sources.
Researchers can now design nucleic acid medicines for specific genetic targets, but delivering those medicines to the right cells and tissues remains a major challenge. Advances in nucleic acid therapeutics have greatly expanded treatment options for various genetic and metabolic diseases, especially those affecting the liver. Beyond chemical stabilization of nucleic acids, much of the progress has come from achieving efficient, cell-specific delivery. A key factor in this success is the development of chemically engineered bioconjugates, such as the N-acetylgalactosamine ligand, which binds selectively to hepatocyte receptors in the liver. This allows for highly efficient delivery of small interfering RNA and antisense oligonucleotides. However, replicating this delivery efficiency in tissues outside the liver (extrahepatic) remains a major challenge. The main obstacle is the lack of well-defined ligand–receptor pairs that mediate cell-specific recognition and uptake in extrahepatic organs. This discussion paper examines how artificial intelligence and machine learning can accelerate the discovery of new chemical ligands for targeted nucleic acid delivery to tissues outside the liver. Taken together, the methods these tools support could enable targeting of organs that are difficult to reach with nucleic acid-based therapies and broaden treatment options for certain cancers and metabolic disorders for which additional treatments are needed.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: